Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The clinical trial of opioid-sparing anesthesia undergoing major laparoscopic abdominal surgery

ABSTRACT: Interventions: Remifentanil group:Remifentanil continuous infused with 0.2-0.5ug/kg/h;Low-opioid anesthesia group:Esketamine and dexmedetomidine continuous infused with 0.2-0.5ug/kg/h Primary outcome(s): Postoperative numeric rating scale pain score Study Design: Parallel

DISEASE(S): Pancreatic Tumors, Liver Tumors, Stomach And Intestinal Tumors

PROVIDER: 40173 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Effects of atomized Esketamine combined with dexmedetomidine on postoperative pharyngalgia and perioperative stress response in patients with colorectal cancer

Project description:Interventions: Blank control group:Preoperative atomization of 5ml normal saline;Esketamine group:Preoperative atomization inhalation of 0.5mg/kg Esketamine plus normal saline to prepare 5ml;Dexmedetomidine group:Atomized inhalation of 1 ug/kg dexmedetomidine plus physiological saline is 5 ml;Dexmedetomidine combined with esketamine group:Atomized inhalation of 0.25mg/kg esketamine +0.5ug/kg dexmedetomidine plus normal saline was configured as 5ml 30min before surgery Primary outcome(s): Incidence of postoperative sore throat Study Design: Parallel

| 88491 | ecrin-mdr-crc

The effect of sub-anaesthetic dose of esketamine on postoperative fatigue of in patients after laparoscopic radical resection of colorectal cancer

Project description:Interventions: group K:a bolus injection of 0.1 mg/kg esketamine intravenously after anesthesia induction, followed by a continuous intravenous infusion of 0.1 mg/kg/h throughout the operation;group C:a bolus injection of 0.1 mg/kg normal saline intravenously after anesthesia induction, followed by a continuous intravenous infusion of 0.1 mg/kg/h throughout the operation Primary outcome(s): identity consequence fatigue scale Study Design: Parallel

| 36609 | ecrin-mdr-crc

RNA sequencing to detect the differentially expressed genes in AngII infused mice after Ethoxysanguinarine, Baicalin, Gastrodin or Valsartan treatment

Project description:The goals of this study is to identify the differential expressed genes in cardiac tissue of C57BL/6 mice with or without Angiotensin II (AngII) treatment, and compare the differential expressed genes in the cardiac tissue of Ang II infused C57BL/6 mice after Ethoxysanguinarine (ETH), Baicalin (BAI), Gastrodin (GAS) or valsartan (VAL) treatment. Briefly, the mice (n=30) were randomly divided into 6 groups: control, AngII, AngII + ETH, AngII + BAI, AngII + GAS and AngII + VAL groups (n=5 for each group). Mice in Control and AngII groups were infused with saline and 500 ng/kg/min of AngII respectively, and orally administrated with saline; the mice in AngII + ETH, AngII + BAI and AngII + GAS groups were infused with AngII (500 ng/kg/min) and orally administrated with 5 mg/kg /day of ETH, BAI or GAS daily for total 4 weeks. The mice in AngII + VAL group were infused with AngII (500 ng/kg/min) and orally administrated with 10.4mg/kg /day of VAL. Then the cardiac tissues were used to identify differentially expressed genes among different groups.

2023-01-09 | GSE193504 | GEO

Ethoxysanguinarine, Baicalin, Gastrodin and Valsartan treatment lower Angiotensin-II-induced blood pressure

Project description:The goals of this study is to identify the differential expressed genes in abdominal aorta of C57BL/6 mice with or without Angiotensin II (AngII) treatment, and compare the differential expressed genes in the abdominal aorta of Ang II infused C57BL/6 mice after Ethoxysanguinarine (ETH), Baicalin (BAI), Gastrodin (GAS) or valsartan (VAL) treatment. Briefly, the mice (n=30) were randomly divided into 6 groups: control, AngII, AngII + ETH, AngII + BAI, AngII + GAS and AngII + VAL groups (n=5 for each group). Mice in Control and AngII groups were infused with saline and 500 ng/kg/min of AngII respectively, and orally administrated with saline; the mice in AngII + ETH, AngII + BAI and AngII + GAS groups were infused with AngII (500 ng/kg/min) and orally administrated with 5 mg/kg /day of ETH, BAI or GAS daily for total 4 weeks. The mice in AngII + VAL group were infused with AngII (500 ng/kg/min) and orally administrated with 10.4mg/kg /day of VAL. Then the abdominal aortas were used to identify differentially expressed genes among different groups.

2021-05-14 | GSE174386 | GEO

The effect of dexmedetomidine on perioperative cholinergic anti-inflammatory pathway and the balance of Th17 / Treg in colorectal cancer patients

Project description:Interventions: DEX: a loading dosage of dexmedetomidine (0.5 ug/Kg) was infused introvenously 10 min before anesthesia and followed continously at0.5 ug/Kg/h for 2h;control:saline Primary outcome(s): interleukin-17, 6, 23, 10, 1ß, TNF-a, TGFß-1, HMGB1, Th17/Treg cell count Study Design: Randomized parallel controlled trial

| 2663054 | ecrin-mdr-crc

Efficacy of olanzapine for relief of nausea with incomplete bowel obstruction in advanced cancer patient: pragmatic randomized controlled trial

Project description:Interventions: Group A: olanzapine (5 mg) Zydis or tablet 5mg/day (evening) orally Group B: 1) metoclopramide (5 mg) tablet 30 mg/day (morning/noon/evening) orally or 2) metoclopramide (10 mg) injectable solution 20 mg/day (intermittent or continuous) subcutaneous or drip infusion Primary outcome(s): Changes in the average value of nausea for 24 hours with Numeric Rating Scale (NRS) Study Design: Parallel Randomized

| 2625706 | ecrin-mdr-crc

RNA sequencing to detect the differentially expressed genes in AngII infused mice model after QDG treatment.

Project description:The mice (n=15) were randomly divided into 3 groups: Control, Ang Ⅱ, and Ang Ⅱ+QDG groups (n = 5 for each group). Mice in Control and Ang Ⅱ groups were infused with saline or 500 ng/kg/min of Ang Ⅱ respectively, and orally administrated with saline; while mice in Ang Ⅱ + QDG group were infused with Ang Ⅱ (500 ng/kg/min) and orally administrated with 1.145 g/kg /day of QDG for 2 weeks. Then the cardiac tissues were used to identify differentially expressed genes among different groups.

2021-08-31 | GSE157127 | GEO

Esketamine Enhances Post-Stroke Microglial Proliferation and Attenuates Neuroinflammation by Disrupting the Src-Pannexin1 Interaction

Project description:Previous research has suggested the potential of esketamine in alleviating post-stroke neuroinflammation, yet the underlying mechanism remained elusive. In our research, we have observed that esketamine increased the number of M2 anti-inflammatory phenotype microglia in the infarcted area after stroke, and this phenomenon is partly associated with the suppression of Panx1. Further research revealed that esketamine suppresses the phosphorylation of sarcoma kinase (Src) at the tyrosine 416 (Y416) site and inhibits the interaction between Src and Panx1, ultimately suppressing the function of Panx1. However, we found esketamine's inhibitory effect on post-stroke Panx1 activation is the underlying mechanism driving the increase in unactivated microglia, yet esketamine's influence on microglial polarization is mediated through a mechanism independent of Panx1.Our research suggests that esketamine, as a drug already used in clinical anesthesia, could potentially provide a solution during the periprocedural period to mitigate the damage caused by aseptic inflammation post-stroke.

2024-09-17 | GSE277009 | GEO

Effect of intravenous lidocaine infusion on postoperative recovery of patients undergoing laparoscopic colorectal surgery

Project description:Interventions: Experimental group:Lidocaine will be infused intravenously, 1.5mg/kg for a single injection, and the continuous infusion volume will be 2mg / kg / h until the end of the operation;Control group:Saline Primary outcome(s): Quality of recovery Study Design: Parallel

| 2688588 | ecrin-mdr-crc

Sedation of children prior to the surgery using nebulization of two doses of a same drug called dexmedetomidine to reduce parental separation anxiety.

Project description:Intervention1: Group B - 39 patients, 3 microgram/kg dexmedetomidine mixed in normal saline to make a total volume of 3 ml.: Group B will receive nebulisation with dexmedetomidine at a dose 3mcg/kg diluted with 0.9% normal saline to a total volume of 3 ml with a nebuliser face mask and a continuous flow of 100% oxygen at 6 L/min for 10 min once before induction of anaesthesia in sitting position. Control Intervention1: Group A - 39 patients, 2 microgram/kg of dexmedetomidine mixed in normal saline to a total volume of 3 ml.: Group A will receive nebulisation with dexmedetomidine at a dose 3mcg/kg diluted with 0.9% normal saline to a total volume of 3 ml with a nebuliser face mask and a continuous flow of 100% oxygen at 6 L/min for 10 min once before induction of anaesthesia in sitting position. Primary outcome(s): Parental seperation anxiety score and mask acceptance scoreTimepoint: 30 mins after beginning of nebulisation. Study Design: Randomized, Parallel Group Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant Blinded

| 2722103 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data